Published in J Exp Med on December 17, 2001
Biofunctionalized magnetic-vortex microdiscs for targeted cancer-cell destruction. Nat Mater (2009) 2.02
Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation. Blood (2015) 1.54
A high-performance nanobio photocatalyst for targeted brain cancer therapy. Nano Lett (2009) 1.19
Lysophosphatidic acid induces interleukin-13 (IL-13) receptor alpha2 expression and inhibits IL-13 signaling in primary human bronchial epithelial cells. J Biol Chem (2007) 1.00
IL-13Rα2 mediates PNR-induced migration and metastasis in ERα-negative breast cancer. Oncogene (2014) 0.83
Interleukin-13 receptor α2 DNA prime boost vaccine induces tumor immunity in murine tumor models. J Transl Med (2010) 0.83
Candidate genes for the progression of malignant gliomas identified by microarray analysis. Neurosurg Rev (2007) 0.82
A new drug delivery method of bispecific ligand-directed toxins, which reduces toxicity and promotes efficacy in a model of orthotopic pancreatic cancer. Pancreas (2010) 0.81
Expression of IL-13Ralpha2 in liver cancer cells and its effect on targeted therapy of liver cancer. J Cancer Res Clin Oncol (2009) 0.80
Therapeutic efficacy of Cintredekin Besudotox (IL13-PE38QQR) in murine lung fibrosis is unaffected by immunity to Pseudomonas aeruginosa exotoxin A. PLoS One (2010) 0.79
Human Hematopoietic Signal peptide-containing Secreted 1 (hHSS1) modulates genes and pathways in glioma: implications for the regulation of tumorigenicity and angiogenesis. BMC Cancer (2014) 0.75
Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem (1980) 28.03
TGFbeta signaling is necessary for carcinoma cell invasiveness and metastasis. Curr Biol (1998) 4.44
An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. Science (1992) 3.78
Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature (1993) 3.67
Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell (1989) 3.43
The chemokine system: redundancy for robust outputs. Immunol Today (1999) 3.40
Interleukin-2 regulates CC chemokine receptor expression and chemotactic responsiveness in T lymphocytes. J Exp Med (1996) 3.30
Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. Clin Cancer Res (2000) 2.61
Cloning and characterization of a binding subunit of the interleukin 13 receptor that is also a component of the interleukin 4 receptor. Proc Natl Acad Sci U S A (1996) 2.57
The murine IL-13 receptor alpha 2: molecular cloning, characterization, and comparison with murine IL-13 receptor alpha 1. J Immunol (1998) 2.57
Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin Cancer Res (2000) 2.22
Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. J Clin Invest (1996) 2.20
A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth. J Exp Med (2000) 1.83
Antitumor effect of locally produced CD95 ligand. Nat Med (1997) 1.82
cDNA cloning and characterization of the human interleukin 13 receptor alpha chain. J Biol Chem (1996) 1.68
Cloning of the human IL-13R alpha1 chain and reconstitution with the IL4R alpha of a functional IL-4/IL-13 receptor complex. FEBS Lett (1997) 1.57
Interleukin-13 receptor alpha chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas. Cancer Res (2000) 1.55
Receptor for interleukin 13. Interaction with interleukin 4 by a mechanism that does not involve the common gamma chain shared by receptors for interleukins 2, 4, 7, 9, and 15. J Biol Chem (1995) 1.52
Cloning and characterization of a specific interleukin (IL)-13 binding protein structurally related to the IL-5 receptor alpha chain. J Biol Chem (1996) 1.43
A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4. J Biol Chem (1995) 1.30
Expression of high affinity interleukin-4 receptors on human renal cell carcinoma cells and inhibition of tumor cell growth in vitro by interleukin-4. J Clin Invest (1993) 1.30
IL-8 reduced tumorigenicity of human ovarian cancer in vivo due to neutrophil infiltration. J Immunol (2000) 1.26
Structure of and signal transduction through interleukin-4 and interleukin-13 receptors (review). Int J Mol Med (1998) 1.21
IL-4 production by human polymorphonuclear neutrophils. J Leukoc Biol (2000) 1.18
The IL-13 receptor structure differs on various cell types and may share more than one component with IL-4 receptor. J Immunol (1997) 1.15
Two different IL-13 receptor chains are expressed in normal human skin fibroblasts, and IL-4 and IL-13 mediate signal transduction through a common pathway. Int Immunol (1998) 1.15
Phenotypic and functional change of cytokine-activated neutrophils: inflammatory neutrophils are heterogeneous and enhance adaptive immune responses. J Leukoc Biol (2001) 1.12
Interleukin-13 sensitivity and receptor phenotypes of human glial cell lines: non-neoplastic glia and low-grade astrocytoma differ from malignant glioma. Cancer Immunol Immunother (2000) 1.07
Structure of IL-13 receptor: analysis of subunit composition in cancer and immune cells. Biochem Biophys Res Commun (1997) 1.06
Receptor for interleukin 13 on AIDS-associated Kaposi's sarcoma cells serves as a new target for a potent Pseudomonas exotoxin-based chimeric toxin protein. Clin Cancer Res (1997) 1.06
Interleukin-13 receptor alpha' but not alpha chain: a functional component of interleukin-4 receptors. Blood (1998) 1.04
Interleukin 13 inhibits growth of human renal cell carcinoma cells independently of the p140 interleukin 4 receptor chain. Clin Cancer Res (1996) 1.02
Role of neutrophils and lymphocytes in inhibition of a mouse mammary adenocarcinoma engineered to release IL-2, IL-4, IL-7, IL-10, IFN-alpha, IFN-gamma, and TNF-alpha. Lab Invest (1996) 0.99
Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer. Cancer Res (2001) 0.98
Inhibition of proliferation and clonal growth of human breast cancer cells by interleukin 13. Cancer Res (1996) 0.96
Expression of high-affinity interleukin 4 receptors on murine sarcoma cells and receptor-mediated cytotoxicity of tumor cells to chimeric protein between interleukin 4 and Pseudomonas exotoxin. Cancer Res (1991) 0.96
Sensitization of cancer cells to interleukin 13-pseudomonas exotoxin-induced cell death by gene transfer of interleukin 13 receptor alpha chain. Hum Gene Ther (2000) 0.93
Down-regulation of interleukin-8 secretion from Mycobacterium tuberculosis-infected monocytes by interleukin-4 and -10 but not by interleukin-13. Infect Immun (2001) 0.91
Identification of distinct roles for a dileucine and a tyrosine internalization motif in the interleukin (IL)-13 binding component IL-13 receptor alpha 2 chain. J Biol Chem (2001) 0.89
Experimental gene therapy of cancer using tumor cells engineered to secrete interleukin-13. Eur J Immunol (1995) 0.89
Structure, function, and targeting of interleukin 4 receptors on human head and neck cancer cells. Cancer Res (2000) 0.88
Interleukin-13 fusion cytotoxin as a potent targeted agent for AIDS-Kaposi's sarcoma xenograft. Blood (2000) 0.87
Conversion of interleukin-13 into a high affinity agonist by a single amino acid substitution. J Biol Chem (2000) 0.85
The extracellular region of heregulin is sufficient to promote mammary gland proliferation and tumorigenesis but not apoptosis. Cancer Res (2000) 0.83
Human ovarian-carcinoma cell lines express IL-4 and IL-13 receptors: comparison between IL-4- and IL-13-induced signal transduction. Int J Cancer (1997) 0.83
Modulation of interleukin (IL)-13 binding and signaling by the gammac chain of the IL-2 receptor. J Biol Chem (1997) 0.82
Gene transfer of interleukin 13 receptor alpha2 chain dramatically enhances the antitumor effect of IL-13 receptor-targeted cytotoxin in human prostate cancer xenografts. Cancer Gene Ther (2001) 0.82
Interleukin-2 receptor gamma chain: a functional component of the interleukin-4 receptor. Science (1993) 4.63
Studies of endotoxin-induced decrease in lipoprotein lipase activity. J Exp Med (1981) 3.70
Lipoprotein lipase suppression in 3T3-L1 cells by an endotoxin-induced mediator from exudate cells. Proc Natl Acad Sci U S A (1982) 3.69
Microtubule-associated-protein (MAP) kinase activated by nerve growth factor and epidermal growth factor in PC12 cells. Identity with the mitogen-activated MAP kinase of fibroblastic cells. Eur J Biochem (1990) 3.06
Lipopolysaccharide-treated RAW 264.7 cells produce a mediator that inhibits lipoprotein lipase in 3T3-L1 cells. J Immunol (1985) 2.15
Water supplementation in exclusively breastfed infants during summer in the tropics. Lancet (1991) 2.09
A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res (1996) 1.90
Stimulation of expression of the human endogenous retrovirus genome by female steroid hormones in human breast cancer cell line T47D. J Virol (1987) 1.75
Effect of prior infection with virulent Shigella flexneri 2a on the resistance of monkeys to subsequent infection with Shigella sonnei. J Infect Dis (1991) 1.69
Selective inhibition of synthesis of enzymes for de novo fatty acid biosynthesis by an endotoxin-induced mediator from exudate cells. Proc Natl Acad Sci U S A (1983) 1.68
cDNA cloning and characterization of the human interleukin 13 receptor alpha chain. J Biol Chem (1996) 1.68
Evaluation of carriers of bone morphogenetic protein for spinal fusion. Spine (Phila Pa 1976) (2001) 1.68
Cisternal irrigation therapy with urokinase and ascorbic acid for prevention of vasospasm after aneurysmal subarachnoid hemorrhage. Outcome in 217 patients. Surg Neurol (2000) 1.65
Filtration leukocytapheresis therapy in rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum (1999) 1.57
Mutual homology of mouse immunoglobulin gamma-chain gene sequences. Biochemistry (1979) 1.55
Interleukin-13 receptor alpha chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas. Cancer Res (2000) 1.55
Ehretianone, a novel quinonoid xanthene from Ehretia buxifolia with antisnake venom activity. J Nat Prod (1996) 1.53
Oral vaccination of monkeys with an invasive Escherichia coli K-12 hybrid expressing Shigella flexneri 2a somatic antigen. Infect Immun (1984) 1.52
Receptor for interleukin 13. Interaction with interleukin 4 by a mechanism that does not involve the common gamma chain shared by receptors for interleukins 2, 4, 7, 9, and 15. J Biol Chem (1995) 1.52
Biochemical characterization and expression analysis of neural thrombospondin-1-like proteins NELL1 and NELL2. Biochem Biophys Res Commun (1999) 1.50
Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin. Clin Cancer Res (1995) 1.50
Interleukin-4 receptor-directed cytotoxin therapy of AIDS-associated Kaposi's sarcoma tumors in xenograft model. Nat Med (1999) 1.48
Cachectin/TNF as well as interleukin-1 induces prostacyclin synthesis in cultured vascular endothelial cells. Biochem Biophys Res Commun (1986) 1.45
Intralesional treatment of established murine primary renal tumor with interleukin-4: localized effect on primary tumor with no impact on metastases. J Urol (1995) 1.44
Interleukin-2 toxicity. J Clin Oncol (1991) 1.40
The amino acid sequence of porcine intestinal calcium-binding protein. Can J Biochem (1979) 1.40
Rapidly progressive interstitial lung disease associated with dermatomyositis responding to intravenous cyclophosphamide pulse therapy. Intern Med (1997) 1.40
Antiphospholipid syndrome with cortical blindness resulting from infarction around the posterior cerebral artery in an elderly woman. Intern Med (2000) 1.40
Safety, immunogenicity, and efficacy in monkeys and humans of invasive Escherichia coli K-12 hybrid vaccine candidates expressing Shigella flexneri 2a somatic antigen. Infect Immun (1992) 1.39
Superiority of acridine orange-stained buffy coat smears for diagnosis of partially treated neonatal septicemia. Acta Paediatr (1993) 1.39
Observations in the diagnosis of cervical myelopathy in patients suffering from diabetes mellitus. Spinal Cord (2012) 1.38
Reversal of multidrug resistance in human colon cancer cells expressing the human MDR1 gene by liposomes in combination with monoclonal antibody or verapamil. J Natl Cancer Inst (1995) 1.37
Charter for care of children in hospitals. Indian Pediatr (1991) 1.37
Relationship of protein structure of isoleucyl-tRNA synthetase with pseudomonic acid resistance of Escherichia coli. A proposed mode of action of pseudomonic acid as an inhibitor of isoleucyl-tRNA synthetase. J Biol Chem (1994) 1.35
Human recombinant TNF suppresses lipoprotein lipase activity and stimulates lipolysis in 3T3-L1 cells. J Biochem (1987) 1.35
Oral submucous fibrosis--treatment with hyalase. J Laryngol Otol (1985) 1.33
Experimental salmonellosis. VII. Comparison of the immunizing effect of live vaccine and materials extracted from Salmonella enteritidis. J Bacteriol (1966) 1.33
The characterization of the common fragile site FRA16D and its involvement in multiple myeloma translocations. Genomics (2000) 1.31
A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4. J Biol Chem (1995) 1.30
Expression of high affinity interleukin-4 receptors on human renal cell carcinoma cells and inhibition of tumor cell growth in vitro by interleukin-4. J Clin Invest (1993) 1.30
A novel human nonviral retroposon derived from an endogenous retrovirus. Nucleic Acids Res (1987) 1.29
Novel anti-brain tumor cytotoxins specific for cancer cells. Nat Biotechnol (1998) 1.28
Perinatal mortality-incidence and effect of various maternal factors, Part I. Indian J Pediatr (1982) 1.28
The Wilms' tumor gene WT1-GFP knock-in mouse reveals the dynamic regulation of WT1 expression in normal and leukemic hematopoiesis. Leukemia (2007) 1.28
Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth. Jpn J Cancer Res (1999) 1.26
Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. Clin Cancer Res (2000) 1.26
IL-13 induces phosphorylation and activation of JAK2 Janus kinase in human colon carcinoma cell lines: similarities between IL-4 and IL-13 signaling. J Immunol (1996) 1.26
Nucleotide sequence of 5S ribosomal RNA from Lingula anatina. A study on the molecular evolution of 5S ribosomal RNA from a living fossil. J Biochem (1980) 1.24
An ion channel of the degenerin/epithelial sodium channel superfamily controls the defecation rhythm in Caenorhabditis elegans. Proc Natl Acad Sci U S A (1998) 1.23
Structure of and signal transduction through interleukin-4 and interleukin-13 receptors (review). Int J Mol Med (1998) 1.21
MKT-077, a novel rhodacyanine dye in clinical trials, exhibits anticarcinoma activity in preclinical studies based on selective mitochondrial accumulation. Cancer Res (1996) 1.21
Receptor for interleukin (IL) 13 does not interact with IL4 but receptor for IL4 interacts with IL13 on human glioma cells. J Biol Chem (1996) 1.21
Expression of high-affinity IL-4 receptors on human melanoma, ovarian and breast carcinoma cells. Clin Exp Immunol (1994) 1.19
A new complement-dependent bactericidal factor found in nonimmune mouse sera: specific binding to polysaccharide of Ra chemotype Salmonella. J Immunol (1982) 1.16
The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes. Leukemia (1999) 1.15
Experimental salmonellosis. X. Cellular immunity and its antibody in mouse mononuclear phagocytes. J Bacteriol (1967) 1.15
The IL-13 receptor structure differs on various cell types and may share more than one component with IL-4 receptor. J Immunol (1997) 1.15
Two different IL-13 receptor chains are expressed in normal human skin fibroblasts, and IL-4 and IL-13 mediate signal transduction through a common pathway. Int Immunol (1998) 1.15
Dynamic changes in cytokine levels in serum and synovial fluid following filtration leukocytapheresis therapy in patients with rheumatoid arthritis. J Clin Apher (2001) 1.15
Nature of the carrier state of bacteriophage SP-10 in Bacillus subtilis. J Bacteriol (1968) 1.14
Mammalian mitochondrial methionyl-tRNA transformylase from bovine liver. Purification, characterization, and gene structure. J Biol Chem (1998) 1.13
The physiological correlates of Kundalini Yoga meditation: a study of a yoga master. Appl Psychophysiol Biofeedback (2001) 1.12
Interleukin-13 receptor as a unique target for anti-glioblastoma therapy. Int J Cancer (2001) 1.09
Risk factors for fatal diarrhea in hospitalized children in India. J Pediatr Gastroenterol Nutr (1991) 1.08
Molecular cloning of retrovirus-like genes present in multiple copies in the Syrian hamster genome. Nucleic Acids Res (1982) 1.08
Long-term WT1 peptide vaccination for patients with acute myeloid leukemia with minimal residual disease. Leukemia (2011) 1.07
Liposome-mediated modulation of multidrug resistance in human HL-60 leukemia cells. J Natl Cancer Inst (1992) 1.07
Spontaneous resolution of chronic subdural hematomas. Neurosurgery (1986) 1.06
Neural and humoral interactions between basal prechiasmatic area and median eminence. Prog Brain Res (1975) 1.06
Structure of IL-13 receptor: analysis of subunit composition in cancer and immune cells. Biochem Biophys Res Commun (1997) 1.06
Apolipoprotein E and lipoprotein lipase secreted from human monocyte-derived macrophages modulate very low density lipoprotein uptake. J Biol Chem (1990) 1.06
A group of bactericidal factors conserved by vertebrates for more than 300 million years. J Immunol (1984) 1.06
Properties of a new complement-dependent bactericidal factor specific for Ra chemotype salmonella in sera of conventional and germ-free mice. J Immunol (1982) 1.06
Receptor for interleukin 13 on AIDS-associated Kaposi's sarcoma cells serves as a new target for a potent Pseudomonas exotoxin-based chimeric toxin protein. Clin Cancer Res (1997) 1.06
The effect of age on lung structure in male BALB/cNNia inbred mice. Am J Anat (1984) 1.05
Development of WT1 peptide cancer vaccine against hematopoietic malignancies and solid cancers. Curr Med Chem (2006) 1.04
Early complications of high-dose methylprednisolone sodium succinate treatment in the follow-up of acute cervical spinal cord injury. Spine (Phila Pa 1976) (2001) 1.04
Posterior endoscopic surgery for lumbar disc herniation with contralateral symptoms - a report of two cases. Minim Invasive Neurosurg (2006) 1.04
Relationship of neurologic status in macaques infected with the simian immunodeficiency virus to cerebrospinal fluid quinolinic acid and kynurenic acid. Brain Res (1992) 1.04
Isolation, characterization and epistasis of fluoride-resistant mutants of Caenorhabditis elegans. Genetics (1994) 1.04
IL-10 inhibits HIV-1 replication and is induced by tat. Biochem Biophys Res Commun (1994) 1.04
Stimulation with thromboxane A2 (TXA2) receptor agonist enhances ICAM-1, VCAM-1 or ELAM-1 expression by human vascular endothelial cells. Clin Exp Immunol (1998) 1.04
Increased clearance of plasma cholesterol after injection of apolipoprotein E into Watanabe heritable hyperlipidemic rabbits. Proc Natl Acad Sci U S A (1989) 1.04
Interleukin-13 receptor alpha' but not alpha chain: a functional component of interleukin-4 receptors. Blood (1998) 1.04
Blood viscosity and plasma viscosity in patients with sudden deafness. Acta Otolaryngol (1994) 1.04
Antiapoptotic function of 17AA(+)WT1 (Wilms' tumor gene) isoforms on the intrinsic apoptosis pathway. Oncogene (2006) 1.02
In situ expression of interleukin-4 (IL-4) receptors in human brain tumors and cytotoxicity of a recombinant IL-4 cytotoxin in primary glioblastoma cell cultures. Cancer Res (2001) 1.02
Preliminary clinical outcome study of mild resuscitative hypothermia after out-of-hospital cardiopulmonary arrest. Resuscitation (1999) 1.02
Interleukin 13 inhibits growth of human renal cell carcinoma cells independently of the p140 interleukin 4 receptor chain. Clin Cancer Res (1996) 1.02
Heterogeneity of B cell responsiveness to interleukin 4, interleukin 6 and low molecular weight B cell growth factor in discrete stages of B cell activation in patients with systemic lupus erythematosus. Clin Exp Immunol (1989) 1.01
Potentiation of cytotoxicity of Kaposi's sarcoma related to immunodeficiency syndrome (AIDS) by liposome-encapsulated doxorubicin. AIDS Res Hum Retroviruses (1993) 1.01
Wilms' tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells. Blood (1998) 1.01
Effects of basic fibroblast growth factor on spontaneous resorption of herniated intervertebral discs. An experimental study in the rabbit. Spine (Phila Pa 1976) (1999) 1.01
Increased vascular permeability in organs mediated by the systemic administration of lymphokine-activated killer cells and recombinant interleukin-2 in mice. J Natl Cancer Inst (1988) 1.01
Shear stress as an inhibitor of vascular smooth muscle cell proliferation. Role of transforming growth factor-beta 1 and tissue-type plasminogen activator. Arterioscler Thromb Vasc Biol (1997) 1.00
Receptors for interleukin (IL)-4 do not associate with the common gamma chain, and IL-4 induces the phosphorylation of JAK2 tyrosine kinase in human colon carcinoma cells. J Biol Chem (1995) 1.00